<?xml version="1.0" encoding="utf-8" ?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>PR.com Press Releases: OYC International, Inc. News</title>
		<link>https://www.PR.com/</link>
		<description>Latest news releases from PR.com for OYC International, Inc.</description>
		<lastBuildDate>Thu, 23 Apr 2026 07:49:58 -0400</lastBuildDate>
		<copyright>&#169; 2026 PR.com</copyright>
		<ttl>60</ttl>
		<language>en-us</language>
		<image>
			<url>https://www.PR.com/images/logo_white.jpg</url>
			<title>PR.com Press Releases: OYC International, Inc. News</title>
			<link>https://www.PR.com/</link>
			<width>68</width>
			<height>69</height>
			<description>PR.com provides press release distribution, and is a unique directory of businesses, products and services. Find full company profiles.</description>
		</image>
		<atom:link href="https://www.pr.com/rss/press-releases-2/69026.xml" rel="self" type="application/rss+xml" />
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/115400</guid>
			<title>Recombinant Human Soluble RANKL (sRANKL) Launched in USA</title>
			<pubDate>Fri, 07 Nov 2008 03:00:00 -0500</pubDate>
			<description>OYC International Inc. is pleased to announce the launch of recombinant human soluble RANKL (sRANKL) to support osteoporosis and bone metabolism research initiatives.  Receptor activator of NF-kB ligand (RANKL), also designated TRANCE, OPGL and ODF, is a member of the TNF family that is expressed in osteoblasts, activated T cells, and so on. RANKL interacts with its receptor RANK expressed on osteoclast progenitors and [PR.com]</description>
			<link>https://www.pr.com/press-release/115400</link>
			<dc:creator>OYC International, Inc.</dc:creator>
		</item>
	</channel>
</rss>